Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move

Key Takeaways Eli Lilly signed a deal worth up to $2.75B with Insilico for AI-driven drug discovery rights.LLY is integrating AI across R&D, using platforms to speed drug discovery and cut timelines. Healthcare ETFs like IHE offer diversified exposure to AI-focused pharma leaders. U.S. pharma giant Eli Lilly (LLY) has just thrust the rapidly evolving field of artificial intelligence (AI)-driven drug discovery into the spotlight, signing a landmark deal worth up to $2.75 billion with Hong Kong-based Insilico ...